Alteration of the Albumin-bound Protein/peptide Complex (ABPPC) is Biomarker for Disease
C04997
Backgrounds
JHU scientists have invented a cost-effective, rapid, and sensitive assay that characterizes proteins differentially bound to albumin in diseased and healthy patients and is compatible with current blood collection protocols. The current hypothesis states that albumin changes with disease, and therefore the complex of albumin and its bound proteins and peptides (ABPPC) changes. The ABPPC assay could measure a modification of albumin or a change in ABPPC composition (i.e. presence/absence of one or more proteins, altered concentration (or stoichiometry or mole ratio) of one or more proteins, change in a protein’s PTM (eg. proteolysis fragment vs intact protein including albumin).
Key Features
Diagnostic assay to screen for proteins bound to albumin
Measure of disease status
Commercial Use
The diagnostic assay will be used to evaluate patients presenting to an emergency room, ongoing care within a hospital setting, to primary care physicians for routine examination, home care, or other medical evaluation for a variety of diseases that alter blood albumin and/or the ABPPC such as myocardial ischemia, myocardial infarction, or vasculitis for example. Advantages include that the ABPPC can be easily and reproducibly obtained from individuals since albumin is highly abundant in serum (40-50 mg/ml).
Stage of Development
Discovery, preclinical
Patent Status
US 8,741,662; EPO 2035830; Japan 5038407; Germany 60 2007 040 808.3
References
PMID: 20204147
Fu et al. 2007 “A rapid, economical, and reproducible method for human serum delipidation and albumin and IgG removal for proteomic analysis”. Methods Mol Biol. 2007;357:365-71
Field
Diagnostics
